The company believes regulatory designations in the US and EU for Netherton Syndrome (NS), with other applications recently submitted in Japan and Saudi Arabia for Orphan Drug Designation and Breakthrough Medicine Designation, respectively, reinforce the potential of QRX003 as a therapeutic candidate as it advances clinical studies towards a potential New Drug Application (NDA). Moreover, the company expects to expand its potential opportunities by advancing its investigator led pediatric NS and Peeling Skin Syndrome (PSS) studies and its Rapamycin program.
